<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2707233934
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Lumakras
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SOTORASIB  
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        240
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        37902.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Inc." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Inc.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Amgen Inc.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LUMAKRAS is a prescription medicine used to treat adults with non‑small cell lung cancer (NSCLC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that has spread to other parts of the body or cannot be removed by surgery, <strong>and</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; whose tumor has an abnormal KRAS G12C gene, <strong>and</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have received at least one prior treatment for their cancer.</p><p>&nbsp;</p><p>Your healthcare provider will perform a test to make sure that LUMAKRAS is right for you.</p><p>It is not known if LUMAKRAS is safe and effective in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take LUMAKRAS</strong> if you are allergic to sotorasib or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor, pharmacist, or nurse before taking LUMAKRAS.</p><p>&nbsp;</p><p>Before taking LUMAKRAS, tell your healthcare provider about all your medical conditions, including if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have lung or breathing problems other than lung cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant. It is not known if LUMAKRAS will harm your unborn baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS and for 1 week after the final dose.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><strong>&nbsp;</strong></p><p>LUMAKRAS has not been studied in children or adolescents. Treatment with LUMAKRAS is not recommended in persons under 18&nbsp;years of age.</p><p>&nbsp;</p><p><strong>Other medicines and LUMAKRAS</strong></p><p><strong>&nbsp;</strong></p><p>Tell your healthcare provider about all the medicines you take, including prescription and over‑the‑counter medicines, vitamins, dietary, and herbal supplements. LUMAKRAS can affect the way some other medicines work and some other medicines can affect the way LUMAKRAS works.</p><p><strong>&nbsp;</strong></p><p>Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H<sub>2</sub> blockers during treatment with LUMAKRAS. Ask your healthcare provider if you are not sure.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>Before starting treatment you must tell your doctor if you are pregnant or breast-feeding, think you may be pregnant or you are planning to have a baby.</p><p>&nbsp;</p><p>You should not become pregnant while taking this medicine because it could harm the baby. This is because the effects of LUMAKRAS in pregnant women are not known. If you are able to become pregnant, you must use highly effective contraception while on treatment and for at least 7&nbsp;days after stopping treatment.</p><p>&nbsp;</p><p>Do not breast-feed while taking this medicine and for 7&nbsp;days after the last dose. This is because it is not known whether the ingredients in LUMAKRAS pass into breast milk and could therefore harm your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>LUMAKRAS has no marked influence on the ability to drive and use machines.</p><p>&nbsp;</p><p><strong>LUMAKRAS contains lactose</strong></p><p>&nbsp;</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p><strong>LUMAKRAS contains sodium</strong></p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take LUMAKRAS exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking LUMAKRAS unless your healthcare provider tells you to.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take LUMAKRAS 1 time each day, at about the same time each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take LUMAKRAS with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow LUMAKRAS tablets whole. Do not chew, crush, or split tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you cannot swallow LUMAKRAS tablets whole:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place your daily dose of LUMAKRAS in a glass of 120 mL of non‑carbonated, room temperature water without crushing the tablets. Do not use any other liquids.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stir until the tablets are in small pieces (the tablets will not completely dissolve). The color of the mixture may be pale yellow to bright yellow.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drink the LUMAKRAS and water mixture right away or within 2 hours of preparing. Do not chew pieces of the tablet.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rinse the glass with an additional 120 mL of water and drink to make sure that you have taken the full dose of LUMAKRAS.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you do not drink the mixture right away, stir the mixture again before drinking.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take an antacid medicine, take LUMAKRAS either 4 hours before or 10 hours after the antacid.</p><p>&nbsp;</p><p><strong>If you take more LUMAKRAS than you should</strong></p><p>&nbsp;</p><p>Contact your doctor, pharmacist or nurse immediately if you take more tablets than recommended.</p><p>&nbsp;</p><p><strong>If you vomit after taking LUMAKRAS</strong></p><p>&nbsp;</p><p>If you vomit after taking a dose of LUMAKRAS, do not take an extra dose. Take your next dose at your regular scheduled time.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take LUMAKRAS</strong></p><p>&nbsp;</p><p>If you miss a dose of LUMAKRAS, take the dose as soon as you remember. If it has been more than 6 hours, do not take the dose. Take your next dose at your regularly scheduled time the next day. Do not take 2 doses at the same time to make up for a missed dose.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>LUMAKRAS may cause serious side effects, including:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Liver problems.</strong> LUMAKRAS may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including:</p><table border="0" cellspacing="0" cellpadding="0" style="width:597px"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your skin or the white part of your eyes turns yellow (jaundice)</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dark or &ldquo;tea‑colored&rdquo; urine</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; light‑colored stools (bowel movements)</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness or weakness</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea or vomiting</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding or bruising</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, aching, or tenderness on the right side of your stomach‑area (abdomen)</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lung or breathing problems.</strong> LUMAKRAS may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever.</p><p>&nbsp;</p><p>Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS if you develop side effects.</p><p>&nbsp;</p><p><strong>The most common side effects of LUMAKRAS include:</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:620px"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle or bone pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in liver function tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in certain other blood tests</p><p>&nbsp;</p></td></tr></tbody></table><p>These are not all the possible side effects of LUMAKRAS.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store LUMAKRAS at room temperature between 20&deg;C to 25&deg;C. Excursions permitted from 15&deg;C to 30&deg;C.</p><p>&nbsp;</p><p>The bottle has a child-resistant closure</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Active Ingredient:</strong> sotorasib</p><p><strong>Inactive Ingredients:</strong> microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. Tablet film coating material contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide yellow.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
	
	LUMAKRAS is supplied as a yellow, oblong-shaped, film-coated tablet, with “AMG” on one side and “120” on the other side.
	
LUMAKRAS is provided in two pack sizes
Pack of 1: a bottle containing 240 film-coated tablets (1 carton with 1 bottle)
Pack of 2: 2 bottles containing 120 film-coated tablets (1 carton with 2 bottles).

Not all pack sizes may be marketed
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p>Amgen Inc.</p><p>One Amgen Center Drive</p><p>Thousand Oaks, CA 91320-1799, USA</p><p>&nbsp;</p><p><strong>Site of Manufacture of the Drug Product:</strong></p><p>Patheon Inc.</p><p>2100 Syntex Court</p><p>Mississauga, Ontario L5N 7K9</p><p>Canada</p><p>&nbsp;</p><p>For more information about this medicine, please contact the local representative of the Marketing Authorization Holder.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in May 2021.
	
This Patient Information has been approved by the U.S. Food and Drug Administration.


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">لوماكراس هو دواء يُصرف بوصفة طبية يُستخدم لعلاج البالغين المصابين بسرطان الرئة ذي الخلايا غير الصغيرة (NSCLC):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذين انتشر السرطان لديهم إلى أجزاء أخرى من الجسم أو لا يمكن إزالته جراحيًا،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>و</strong>الذين يشتمل الورم لديهم على جين KRAS G12C غير طبيعي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>و</strong>الذين تلقوا علاجًا واحدًا للسرطان على الأقل في السابق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يجري مقدم الرعاية الصحية الخاص بك اختبارًا للتأكد من أن لوماكراس مناسب لك.</p><p dir="RTL">من غير المعروف ما إذا كان لوماكراس آمنًا وفعالًا لدى الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم دواء لوماكراس</strong> إذا كنت تعاني من حساسية تجاه سوتوراسيب أو أي من المُكونات الأخرى لهذا الدواء (المذكورة في القسم&nbsp;٦).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرض(ة) قبل استخدام دواء لوماكراس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل تناول لوماكراس، أخبر مقدم الرعاية الصحية الخاص بك عن كل حالاتك الطبية، بما في ذلك ما إذا كنت:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تعاني من مشاكل في الكبد.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تعاني من مشاكل في الرئة أو في التنفس غير سرطان الرئة.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>حاملاً أو تخططين للحمل. من غير المعروف ما إذا كان لوماكراس سيؤذي جنينك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترضعين رضاعة طبيعية أو تخططين للإرضاع طبيعيا. من غير المعروف ما إذا كان لوماكراس يُفرز في لبن الأم. لا يجب عليك الإرضاع أثناء العلاج بلوماكراس ولمدة أسبوع واحد بعد الجرعة النهائية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لم يتم دراسة لوماكراس لدى الأطفال والمراهقين. لا ينصح بالمعالجة بلوماكراس عند الأشخاص الذين يقل عمرهم عن ١٨ عاماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى ولوماكراس</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يرجى إخبار مقدم الرعاية الصحية بشأن كل الأدوية التي تتناولها، بما في ذلك الأدوية التي تُصرف بوصفة طبية وتلك التي تُصرف بدون وصفة طبية، والفيتامينات والمكمّلات الغذائية والعشبية. يمكن أن يؤثر لوماكراس على طريقة عمل الأدوية الأخرى ويمكن أن تؤثر بعض الأدوية الأخرى على طريقة عمل لوماكراس.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يرجى إخبار مقدم الرعاية الصحية الخاص بك على وجه الخصوص إذا كنت تتناول أدوية مضادة للحموضة، بما في ذلك الأدوية المثبطة لمضخة البروتون (PPI) أو حاصرات H&lrm;<sub>2</sub><sub>&lrm;</sub>&lrm;&rlm; أثناء العلاج بلوماكراس. استشر مقدم الرعاية الصحية الخاص بك إذا لم تكن متأكدًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملا أو ترضعين رضاعة طبيعية، أو تشكين أنك حاملاً، أو تخططين للحمل، فيجب عليكِ استشارة طبيبك قبل البدء بالعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليكِ الامتناع عن الحمل أثناء تناول هذا الدواء فقد يؤذي ذلك الجنين. هذا لأنه من غير المعروف تأثير لوماكراس لدى النساء الحوامل. إذا كانت لديكِ القدرة على الحمل، فعليكِ استخدام وسائل منع حمل فعالة للغاية أثناء العلاج و لمدة ٧ أيام على الأقل بعد إيقاف العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقومي بالرضاعة الطبيعية أثناء تناول هذا الدواء و لمدة ٧ أيام من الجرعة النهائية. ذلك لأنه من غير المعروف إذا ما كانت مكونات لوماكراس تُفرز في لبن الأم وبالتالي يمكنها أن تؤذي طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ليس لدى لوماكراس تأثيراً ملحوظاً على قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي دواء لوماكراس على اللاكتوز</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أخبرك طبيبك بأنه لديك عدم تحمل لبعض السكريات، فقم باستشارة طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي دواء لوماكراس على الصوديوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على أقل من ١&nbsp;مليمول من الصوديوم (٢٣&nbsp;مجم) لكل قرص، أي أنه &quot;خال من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول لوماكراس بدقّة على النحو الذي يصفه لك مقدم الرعاية الصحية الخاص بك. لا تغير جرعتك أو تتوقف عن تناول لوماكراس ما لم يخبرك مقدم الرعاية الصحية الخاص بك بذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول لوماكراس مرة واحدة كل يوم، في نفس الوقت من اليوم تقريبًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول لوماكراس مع الطعام أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع أقراص لوماكراس كاملة. لا تمضغ الأقراص أو تسحقها أو تقسمها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تكن تستطيع ابتلاع أقراص لوماكراس كاملة:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع جرعتك اليومية من لوماكراس في كوب ١٢٠&nbsp;مل من المياه غير المكربنة في درجة حرارة الغرفة من دون سحق الأقراص. لا تستخدم أي سوائل أخرى.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرّك المزيج حتى تصبح الأقراص أجزاءً صغيرة (لن تتحلل الأقراص بشكل كامل). قد يكون لون المزيج ما بين الأصفر الباهت والأصفر الفاتح.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اشرب مزيج لوماكراس والمياه على الفور أو خلال ساعتين من التحضير. لا تمضغ أجزاء القرص.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اشطف الكوب بمقدار ١٢٠&nbsp;مل إضافية من المياه واشربها للتأكد من أنك قد تناولت جرعة لوماكراس الكاملة.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال لم تشرب المزيج على الفور، يرجى تحريك المزيج مرة أخرى قبل شربه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال كنت تتناول دواءً مضادًا للحموضة، تناول لوماكراس قبل تناول مضاد الحموضة بـ ٤&nbsp;ساعات أو بعده بـ ١٠&nbsp;ساعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعة أكثر من المطلوب من دواء لوماكراس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بالطبيب أو الصيدلي أو الممرض(ة) على الفور في حال كنت قد تعاطيت أكثر من الجرعة الموصوفة من الأقراص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال القيء بعد تناول جرعة من دواء لوماكراس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال القيء بعد تناول جرعة من لوماكراس، لا تتناول جرعة إضافية. تناول جرعتك التالية في الوقت المحدد المعتاد من اليوم التالي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت تناول دواء لوماكراس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا فاتتك جرعة من لوماكراس، فتناولها حالما تتذكرها. في حال مرور أكثر من ٦&nbsp;ساعات على موعد الجرعة، لا تتناولها. تناول جرعتك التالية في الوقت المحدد المعتاد من اليوم التالي. لا تتناول جرعتين في الوقت نفسه لتعويض جرعة فائتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في ظهور آثار جانبية، على الرغم من أنها لا تظهر لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يسبب لوماكراس آثارًا جانبية وخيمة، من بينها:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل في الكبد.</strong> قد يؤدي لوماكراس إلى نتائج غير طبيعية لفحص الدم الخاص بالكبد. يجب على مقدم الرعاية الصحية الخاص بك إجراء فحوصات دم قبل بدء العلاج بلوماكراس وفي أثنائه للتحقق من وظيفة الكبد لديك. أخبر مقدم الرعاية الصحية الخاص بك على الفور إذا ظهرت عليك أي علامات أو أعراض لمشاكل الكبد، بما في ذلك:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:597px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار بشرتك أو الجزء الأبيض من عينيك (اليرقان)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحول لون البول إلى اللون الداكن أو &quot;لون الشاي&quot;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحول لون البراز (التغوط) إلى اللون الفاتح</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرهاق أو الضعف</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان أو القيء</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف أو الكدمات</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم أو الوجع أو التورم في الجانب الأيمن من منطقة المعدة (البطن)</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل الرئة أو التنفس.</strong> قد يسبب لوماكراس التهاب الرئتين الذي يمكن أن يؤدي إلى الوفاة. أخبر مُقدم الرعاية الصحية الخاص بك او احصل على مساعدة طبية طارئة على الفور إذا أصبحت تعاني مؤخرًا من ضيق التنفس أو السعال أو الحمى، أو إذا ازدادت حالتك سوءًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يغير مقدم الرعاية الصحية الخاص بك جرعتك أو يوقف العلاج بلوماكراس مؤقتًا أو بصفة دائمة في حال ظهور آثار جانبية لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تشمل الآثار الجانبية الأكثر شيوعًا لدواء لوماكراس:</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:620px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات أو العظام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرهاق</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في فحوصات وظائف الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في فحوصات دم محددة أخرى</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">وهذه ليست كل الآثار الجانبية المحتملة للوماكراس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرضت لأية آثار جانبية، فتحدث إلى الطبيب أو الصيدلي الخاص بك. ويتضمن ذلك أية آثار جانبية محتملة لم يرد ذكرها في هذه النشرة. بالإبلاغ عن الآثار الجانبية، فإنك بذلك تساهم في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المطبوع على ملصق العلبة بعد كلمة (EXP). يُشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخزّن لوماكراس في درجة حرارة الغرفة ما بين ٢٠&nbsp;درجة مئوية و٢٥&nbsp;درجة مئوية. يسمح بالتفاوت من ١٥ درجة مئوية إلى ٣٠ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشتمل الزجاجة على خاصية إغلاق مقاومة لعبث الأطفال لضمان سلامتهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أية أدوية ضمن نفايات المنزل أو الصرف الصحي. استفسر من الصيدلي عن طرق التخلص من الأدوية التي لم تعد قيد الاستخدام. فهذه التدابير من شأنها المساعدة على الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المكون الفعال:</strong> سوتوراسيب.</p><p dir="RTL"><strong>المُكوّنات غير الفعالة:</strong> السليولوز البلوري المكرويّ، اللاكتوز أحادي الماء، كروسكارميلوز الصوديوم، ستيرات المغنيزيوم. تحتوي مادة تغليف الأقراص على كحول البولي فينيل، ثنائي أكسيد التيتانيوم، غليكول البولي إيثيلين، التالك، وأكسيد الحديد الأصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو دواء لوماكراس وما هي محتويات العبوة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر لوماكراس على شكل أقراص مغلفة صفراء اللون، مستطيلة الشكل محفورعلى وجه منها &quot;120&quot; و على الوجه الآخر &quot;AMG&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر لوماكراس في أحجام العبوات التالية</p><p dir="RTL">عبوة واحدة: عبوة تحتوي على ٢٤٠ قرص مغلف (علبة تحتوي على عبوة واحدة)</p><p dir="RTL">عبوتان: عبوتان تحتوي كل واحدة منهما على ١٢٠ قرص مغلف (علبة تحتوي على عبوتان).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في الأسواق.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب ترخيص التسويق والجهة المصنعة</strong></p><p dir="RTL">.Amgen Inc&lrm;</p><p dir="RTL">One Amgen Center Drive</p><p dir="RTL">Thousand Oaks, CA 91320-1799<br />الولايات المتحدة الأمريكية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موقع تصنيع المُنتج الدوائي</strong></p><p dir="RTL">.Patheon Inc&lrm;</p><p dir="RTL">Syntex Court&rlm; 2100&lrm;</p><p dir="RTL">Mississauga, Ontario L5N 7K9</p><p dir="RTL">كندا</p><p dir="RTL">&nbsp;</p><p dir="RTL">لمزيد من المعلومات عن هذا الدواء، يرجى الاتصال بالممثل المحلي لصاحب ترخيص التسويق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في مايو ٢٠٢١.
	
تمت الموافقة على نشرة معلومات المريض هذه من قبل إدارة الغذاء والدواء الأمريكية.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LUMAKRAS™ 120 mg film-coated tablets


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 120 mg of sotorasib.
Sotorasib is an inhibitor of the RAS GTPase family. The molecular formula is C30H30F2N6O3, and the molecular weight is 560.6 g/mol. The chemical name of sotorasib is 6 fluoro 7 (2 fluoro 6 hydroxyphenyl) (1M) 1 [4 methyl 2 (propan 2 yl)pyridin 3 yl] 4 [(2S) 2  methyl 4 (prop 2 enoyl)piperazin 1 yl]pyrido[2,3 d]pyrimidin 2(1H) one.

Sotorasib has pKa values of 8.06 and 4.56. The solubility of sotorasib in the aqueous media decreases over the range pH 1.2 to 6.8 from 1.3 mg/mL to 0.03 mg/mL.

LUMAKRAS is supplied as film coated tablets for oral use containing 120 mg of sotorasib. Inactive ingredients in the tablet core are microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. The film coating material consists of polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide yellow.

Excipient with known effect

Each film-coated tablet contains 114 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.

Yellow, oblong shaped, immediate release, film-coated, debossed with “AMG” on one side and “120” on the opposite side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LUMAKRAS is indicated for the treatment of adult patients with <em>KRAS G12C</em>‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC), as determined by an approved test (see section 4.2)<em>,</em> who have received at least one prior systemic therapy.</p><p>&nbsp;</p><p>This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Patient selection</u></p><p>&nbsp;</p><p>Select patients for treatment of locally advanced or metastatic NSCLC with LUMAKRAS based on the presence of KRAS G12C mutation in tumor or plasma specimens. If no mutation is detected in a plasma specimen, test tumor tissue.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dosage of LUMAKRAS is 960&nbsp;mg (eight 120&nbsp;mg tablets) orally once daily until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Take LUMAKRAS at the same time each day with or without food (see section 4.4). Swallow tablets whole. Do not chew, crush or split tablets. If a dose of LUMAKRAS is missed by more than 6 hours, take the next dose as prescribed the next day. Do not take 2 doses at the same time to make up for the missed dose.</p><p>&nbsp;</p><p>If vomiting occurs after taking LUMAKRAS, do not take an additional dose. Take the next dose as prescribed the next day.</p><p>&nbsp;</p><p><u>Dosage Modifications for Adverse Reactions</u></p><p>&nbsp;</p><p>LUMAKRAS dose reduction levels are summarized in Table 1. Dosage modifications for adverse reactions are provided in Table 2.</p><p>&nbsp;</p><p>If adverse reactions occur, a maximum of two dose reductions are permitted. Discontinue LUMAKRAS if patients are unable to tolerate the minimum dose of 240&nbsp;mg once daily.</p><p>&nbsp;</p><p><strong>Table 1. Recommended LUMAKRAS Dose Reduction Levels for Adverse Reactions</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dose Reduction Level</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>First dose reduction</p></td><td style="vertical-align:top"><p>480&nbsp;mg (4 tablets) once daily</p></td></tr><tr><td style="vertical-align:top"><p>Second dose reduction</p></td><td style="vertical-align:top"><p>240&nbsp;mg (2 tablets) once daily</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 2. Recommended LUMAKRAS Dosage Modifications for Adverse Reactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:636px"><thead><tr><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>Severity<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Dosage Modification</strong></p></td></tr></thead><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Hepatotoxicity (see section 4.4)</p></td><td style="vertical-align:top"><p>Grade 2 AST or ALT with symptoms</p><p>or</p><p>Grade 3 to 4 AST or ALT</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Withhold LUMAKRAS until recovery to &le;&nbsp;Grade 1 or baseline.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Resume LUMAKRAS at the next lower dose level.</p></td></tr><tr><td style="vertical-align:top"><p>AST or ALT &gt; 3 &times; ULN with total bilirubin &gt; 2 &times; ULN in the absence of alternative causes</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue LUMAKRAS.</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial Lung Disease (ILD)/ pneumonitis (see section 4.4)</p></td><td style="vertical-align:top"><p>Any Grade</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Withhold LUMAKRAS if ILD/pneumonitis is suspected.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue LUMAKRAS if ILD/pneumonitis is confirmed.</p><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p>Nausea or vomiting despite appropriate supportive care (including anti‑emetic therapy)</p><p>(see section 4.8)</p></td><td style="vertical-align:top"><p>Grade 3 to 4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Withhold LUMAKRAS until recovery to &le;&nbsp;Grade 1 or baseline.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Resume LUMAKRAS at the next lower dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea despite appropriate supportive care (including anti‑diarrheal therapy)</p><p>(see section 4.8)</p></td><td style="vertical-align:top"><p>Grade 3 to 4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Withhold LUMAKRAS until recovery to &le;&nbsp;Grade 1 or baseline.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Resume LUMAKRAS at the next lower dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Other adverse reactions</p><p>(see section 4.8)</p></td><td style="vertical-align:top"><p>Grade 3 to 4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Withhold LUMAKRAS until recovery to &le;&nbsp;Grade 1 or baseline.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Resume LUMAKRAS at the next lower dose level.</p></td></tr></tbody></table><p>ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal</p><p>a Grading defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0</p><p>&nbsp;</p><p><u>Coadministration of LUMAKRAS with Acid‑Reducing Agents</u></p><p>&nbsp;</p><p>Avoid coadministration of proton pump inhibitors (PPIs) and H<sub>2</sub> receptor antagonists with LUMAKRAS. If treatment with an acid‑reducing agent cannot be avoided, take LUMAKRAS 4 hours before or 10 hours after administration of a local antacid (see section 4.5 and section 5.2).</p><p>&nbsp;</p><p><u>Administration to Patients Who Have Difficulty Swallowing Solids</u></p><p>&nbsp;</p><p>Disperse tablets in 120&nbsp;mL (4 ounces) of non‑carbonated, room‑temperature water without crushing. No other liquids should be used. Stir until tablets are dispersed into small pieces (the tablets will not completely dissolve) and drink immediately or within 2 hours. The appearance of the mixture may range from pale yellow to bright yellow. Swallow the tablet dispersion. Do not chew pieces of the tablet. Rinse the container with an additional 120&nbsp;mL of water and drink. If the mixture is not consumed immediately, stir the mixture again to ensure that tablets are dispersed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hepatotoxicity</u></p><p>&nbsp;</p><p>LUMAKRAS can cause hepatotoxicity, which may lead to drug‑induced liver injury and hepatitis. Among 357&nbsp;patients who received LUMAKRAS in CodeBreaK 100 (see section 4.8), hepatotoxicity occurred in 1.7% (all grades) and 1.4% (Grade 3). A total of 18% of patients who received LUMAKRAS had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); 6% were Grade 3 and 0.6% were Grade 4. The median time to first onset of increased ALT/AST was 9 weeks (range: 0.3 to 42). Increased ALT/AST leading to dose interruption or reduction occurred in 7% of patients. LUMAKRAS was discontinued due to increased ALT/AST in 2.0% of patients. In addition to dose interruption or reduction, 5% of patients received corticosteroids for the treatment of hepatotoxicity.</p><p>&nbsp;</p><p>Monitor liver function tests (ALT, AST, and total bilirubin) prior to the start of LUMAKRAS, every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations. Withhold, dose reduce or permanently discontinue LUMAKRAS based on severity of adverse reaction<em> </em>(see section 4.2 and section 4.8)</p><p>&nbsp;</p><p><u>Interstitial Lung Disease (ILD)/Pneumonitis</u></p><p>&nbsp;</p><p>LUMAKRAS can cause ILD/pneumonitis that can be fatal. Among 357 patients who received LUMAKRAS in CodeBreaK 100 (see section 4.8), ILD/pneumonitis occurred in 0.8% of patients, all cases were Grade&nbsp;3 or 4 at onset, and 1 case was fatal. The median time to first onset for ILD/pneumonitis was 2 weeks (range:&nbsp;2 to 18 weeks). LUMAKRAS was discontinued due to ILD/pneumonitis in 0.6% of patients. Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold LUMAKRAS in patients with suspected ILD/pneumonitis and permanently discontinue LUMAKRAS if no other potential causes of ILD/pneumonitis are identified (see section 4.2 and section 4.8).</p><p>&nbsp;</p><p><u>Lactose intolerance</u></p><p>&nbsp;</p><p>LUMAKRAS contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose‑galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Effects of Other Drugs on LUMAKRAS</u></em></p><p><u>&nbsp;</u></p><p><u>Acid‑Reducing Agents</u></p><p>&nbsp;</p><p>Coadministration of LUMAKRAS with gastric acid‑reducing agents decreased sotorasib concentrations (see section 5.2),<em> </em>which may reduce the efficacy of sotorasib. Avoid coadministration of LUMAKRAS with proton pump inhibitors (PPIs), H<sub>2</sub> receptor antagonists, and locally acting antacids. If coadministration with an acid‑reducing agent cannot be avoided, administer LUMAKRAS 4 hours before or 10&nbsp;hours after administration of a locally acting antacid (see section 4.2)<em> </em></p><p><u>&nbsp;</u></p><p><u>Strong CYP3A4 Inducers</u></p><p>&nbsp;</p><p>Coadministration of LUMAKRAS with a strong CYP3A4 inducer decreased sotorasib concentrations (see section 5.2)<em>, </em>which may reduce the efficacy of sotorasib. Avoid coadministration of LUMAKRAS with strong CYP3A4 inducers<em>.</em></p><p><em>&nbsp;</em></p><p><em><u>Effects of LUMAKRAS on Other Drugs</u></em></p><p><u>&nbsp;</u></p><p><u>CYP3A4 Substrates</u></p><p>&nbsp;</p><p>Coadministration of LUMAKRAS with a CYP3A4 substrate decreased its plasma concentrations (see section 5.2), which may reduce the efficacy of the substrate. Avoid coadministration of LUMAKRAS with CYP3A4 sensitive substrates, for which minimal concentration changes may lead to therapeutic failures of the substrate. If coadministration cannot be avoided, increase the sensitive CYP3A4 substrate dosage in accordance with its Prescribing Information<em>.</em></p><p><em>&nbsp;</em></p><p><u>P‑glycoprotein (P‑gp) Substrates</u></p><p><em><u>&nbsp;</u></em></p><p>Coadministration of LUMAKRAS with a P‑gp substrate (digoxin) increased digoxin plasma concentrations (see section 5.2), which may increase the adverse reactions of digoxin. Avoid coadministration of LUMAKRAS with P‑gp substrates, for which minimal concentration changes may lead to serious toxicities. If coadministration cannot be avoided, decrease the P‑gp substrate dosage in accordance with its Prescribing Information<em>.</em></p><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p><em>Risk Summary</em></p><p>&nbsp;</p><p>There are no available data on LUMAKRAS use in pregnant women. In rat and rabbit embryo‑fetal development studies, oral sotorasib did not cause adverse developmental effects or embryo‑lethality at exposures up to 4.6 times the human exposure at the 960&nbsp;mg clinical dose (see Data)</p><p>&nbsp;</p><p><em>Data</em></p><p><u>&nbsp;</u></p><p><em>Animal Data</em></p><p>&nbsp;</p><p>In a rat embryo‑fetal development study, once daily oral administration of sotorasib to pregnant rats during the period of organogenesis resulted in maternal toxicity at the 540&nbsp;mg/kg dose level (approximately 4.6 times the human exposure based on area under the curve (AUC) at the clinical dose of 960&nbsp;mg). Sotorasib did not cause adverse developmental effects and did not affect embryo‑fetal survival at doses up to 540&nbsp;mg/kg.</p><p>&nbsp;</p><p>In a rabbit embryo‑fetal development study, once daily oral administration of sotorasib during the period of organogenesis resulted in lower fetal body weights and a reduction in the number of ossified metacarpals in fetuses at the 100&nbsp;mg/kg dose level (approximately 2.6 times the human exposure based on AUC at the clinical dose of 960&nbsp;mg), which was associated with maternal toxicity including decreased body weight gain and food consumption during the dosing phase. Sotorasib did not cause adverse developmental effects and did not affect embryo‑fetal survival at doses up to 100&nbsp;mg/kg.</p><p>&nbsp;</p><p><u>Lactation</u></p><p>&nbsp;</p><p><em>Risk Summary</em></p><p>&nbsp;</p><p>There are no data on the presence of sotorasib or its metabolites in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LUMAKRAS and for 1 week after the final dose.</p><p>&nbsp;</p><p><u>Pediatric Use</u></p><p>&nbsp;</p><p>The safety and effectiveness of LUMAKRAS have not been established in pediatric patients.</p><p>&nbsp;</p><p><u>Geriatric Use</u></p><p>&nbsp;</p><p>Of the 357 patients with any tumor type who received LUMAKRAS 960&nbsp;mg orally once daily in CodeBreaK 100, 46% were 65 and over, and 10% were 75 and over. No overall differences in safety or effectiveness were observed between older patients and younger patients.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LUMAKRAS has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatotoxicity (see section 4.4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interstitial Lung Disease (ILD)/Pneumonitis (see section 4.4)</p><p><em>&nbsp;</em></p><p><u>Clinical Trials Experience</u></p><p>&nbsp;</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p>The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to LUMAKRAS as a single agent at 960&nbsp;mg orally once daily in 357 patients with NSCLC and other solid tumors with <em>KRAS G12C</em> mutation enrolled in CodeBreaK 100, 28% were exposed for 6 months or longer and 3% were exposed for greater than one year.</p><p>&nbsp;</p><p><u>Non‑Small Cell Lung Cancer</u></p><p><u>&nbsp;</u></p><p>The safety of LUMAKRAS was evaluated in a subset of patients with <em>KRAS G12C</em>‑mutated locally advanced or metastatic NSCLC in CodeBreaK 100<em>. </em>Patients received LUMAKRAS 960&nbsp;mg orally once daily until disease progression or unacceptable toxicity (n = 204). Among patients who received LUMAKRAS, 39% were exposed for 6 months or longer and 3% were exposed for greater than one year.</p><p>&nbsp;</p><p>The median age of patients who received LUMAKRAS was 66 years (range: 37 to 86); 55% female; 80% White, 15% Asian, and 3% Black.</p><p>&nbsp;</p><p>Serious adverse reactions occurred in 50% of patients treated with LUMAKRAS. Serious adverse reactions in &ge; 2% of patients were pneumonia (8%), hepatotoxicity (3.4%), and diarrhea (2%). Fatal adverse reactions occurred in 3.4% of patients who received LUMAKRAS due to respiratory failure (0.8%), pneumonitis (0.4%), cardiac arrest (0.4%), cardiac failure (0.4%), gastric ulcer (0.4%), and pneumonia (0.4%).</p><p>&nbsp;</p><p>Permanent discontinuation of LUMAKRAS due to an adverse reaction occurred in 9% of patients. Adverse reactions resulting in permanent discontinuation of LUMAKRAS in &ge; 2% of patients included hepatotoxicity (4.9%).</p><p>&nbsp;</p><p>Dosage interruptions of LUMAKRAS due to an adverse reaction occurred in 34% of patients. Adverse reactions which required dosage interruption in &ge; 2% of patients were hepatotoxicity (11%), diarrhea (8%), musculoskeletal pain (3.9%), nausea (2.9%), and pneumonia (2.5%).</p><p>&nbsp;</p><p>Dose reductions of LUMAKRAS due to an adverse reaction occurred in 5% of patients. Adverse reactions which required dose reductions in &ge; 2% of patients included increased ALT (2.9%) and increased AST (2.5%).</p><p>&nbsp;</p><p>The most common adverse reactions (&ge; 20%) were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough. The most common laboratory abnormalities (&ge; 25%) were decreased lymphocytes, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, decreased calcium, increased alkaline phosphatase, increased urine protein, and decreased sodium.</p><p>&nbsp;</p><p>Table 3 summarizes the common adverse reactions observed in CodeBreaK 100.</p><p><strong>&nbsp;</strong></p><p><strong>Table 3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions (&ge; 10%) of Patients With <em>KRAS G12C</em>‑Mutated NSCLC Who Received LUMAKRAS in CodeBreaK 100<sup>*</sup></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:622px"><tbody><tr><td rowspan="2"><p><strong>Adverse Reaction</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>LUMAKRAS</strong></p><p><strong>N&nbsp;=&nbsp;204</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Grades (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 to 4</strong></p><p><strong>(%)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup> a</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatotoxicity<sup>b</sup></p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic, and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>c</sup></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea<sup>d</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>2.9</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup>e</sup></p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>f</sup></p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Edema<sup>g</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia<sup>h</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>i</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup> Grading defined by NCI CTCAE version 5.0.</p><p><sup>a </sup>&nbsp;Abdominal pain includes abdominal pain, abdominal pain upper, and abdominal pain lower.</p><p><sup>b</sup> Hepatotoxicity includes alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, drug‑induced liver injury, hepatitis, hepatotoxicity, liver function test increased, and transaminases increased.</p><p><sup>c</sup> Cough includes cough, productive cough, and upper‑airway cough syndrome.</p><p><sup>d</sup> Dyspnea includes dyspnea and dyspnea exertional.</p><p><sup>e</sup> Musculoskeletal pain includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, myalgia, neck pain, non‑cardiac chest pain, and pain in extremity.</p><p><sup>f </sup>Fatigue includes fatigue and asthenia.</p><p><sup>g</sup> Edema includes generalized edema, localized edema, edema, edema peripheral, periorbital edema, and testicular edema.</p><p><sup>h</sup> Pneumonia includes pneumonia, pneumonia aspiration, pneumonia bacterial, and pneumonia staphylococcal.</p><p><sup>i</sup> Rash includes dermatitis, dermatitis acneiform, rash, rash‑maculopapular, and rash pustular.</p></td></tr></tbody></table><p>&nbsp;</p><p>Table 4 summarizes the selected laboratory adverse reactions observed in CodeBreaK 100.</p><p>&nbsp;</p><p><strong>Table 4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Select Laboratory Abnormalities (&ge; 20%) That Worsened from Baseline in Patients With</strong> <strong><em>KRAS&nbsp;G12C</em>‑Mutated NSCLC Who Received LUMAKRAS in CodeBreaK 100</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Laboratory Abnormalities</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>LUMAKRAS</strong></p><p><strong>N&nbsp;=&nbsp;204*</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grades 1 to 4</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grades 3 to 4</strong></p><p><strong>(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Chemistry</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Increased aspartate aminotransferase</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Increased alanine aminotransferase</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Decreased calcium</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Increased alkaline phosphatase</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>2.5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Increased urine protein</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>3.9</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Decreased sodium</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Decreased albumin</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hematology</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Decreased lymphocytes</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp; </strong>Decreased hemoglobin</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Increased activated partial thromboplastin time</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>1.5</p></td></tr></tbody></table><p>*N&nbsp;=&nbsp;number of patients who had at least one on‑study assessment for the parameter of interest.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local representative.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>To report any side effects:</p><p>Saudi Arabia:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required. There is no specific antidote for overdose with LUMAKRAS.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, ATC code: L01XX73</p><p>&nbsp;</p><p><u>Mechanism of Action</u></p><p>Sotorasib is an inhibitor of KRAS<sup>G12C</sup>, a tumor‑restricted, mutant‑oncogenic form of the RAS GTPase, KRAS. Sotorasib forms an irreversible, covalent bond with the unique cysteine of KRAS<sup>G12C</sup>, locking the protein in an inactive state that prevents downstream signaling without affecting wild‑type KRAS. Sotorasib blocked KRAS signaling, inhibited cell growth, and promoted apoptosis only in <em>KRAS G12C</em> tumor cell lines. Sotorasib inhibited KRAS<sup>G12C</sup> <em>in vitro</em> and <em>in vivo</em> with minimal detectable off‑target activity. In mouse tumor xenograft models, sotorasib‑treatment led to tumor regressions and prolonged survival, and was associated with anti‑tumor immunity in <em>KRAS G12C</em> models.</p><p><u>Pharmacodynamics</u></p><p>Sotorasib exposure‑response relationships and the time course of the pharmacodynamic response are unknown.</p><p><u>Cardiac Electrophysiology</u></p><p>At the approved recommended dosage, LUMAKRAS does not cause large mean increases in the QTc interval (&gt;&nbsp;20&nbsp;msec).</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The efficacy of LUMAKRAS was demonstrated in a subset of patients enrolled in a single‑arm, open‑label, multicenter trial (CodeBreaK 100 [NCT03600883]). Eligible patients were required to have locally advanced or metastatic <em>KRAS G12C</em>‑mutated NSCLC with disease progression after receiving an immune checkpoint inhibitor and/or platinum‑based chemotherapy, an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1, and at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1).</p><p>&nbsp;</p><p>All patients were required to have prospectively identified <em>KRAS G12C</em>‑mutated NSCLC in tumor tissue samples by using the QIAGEN <em>therascreen</em><sup>&reg;</sup> KRAS RGQ PCR Kit performed in a central laboratory. Of 126 total enrolled subjects, 2 (2%) were unevaluable for efficacy analysis due to the absence of radiographically measurable lesions at baseline. Of the 124 patients with <em>KRAS G12C</em> mutations confirmed in tumor tissue, plasma samples from 112 patients were tested retrospectively using the Guardant360<sup>&reg; </sup>CDx. 78/112 patients (70%) had <em>KRAS G12C</em> mutation identified in plasma specimen, 31/112 patients (28%) did not have <em>KRAS G12C</em> mutation identified in plasma specimen and 3/112 (2%) were unevaluable due to Guardant360<sup>&reg; </sup>CDx test failure.</p><p>&nbsp;</p><p>A total of 124 patients had at least one measurable lesion at baseline assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1 and were treated with LUMAKRAS 960&nbsp;mg once daily until disease progression or unacceptable toxicity. The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR) as evaluated by BICR according to RECIST v1.1.</p><p>&nbsp;</p><p>The baseline demographic and disease characteristics of the study population were: median age 64 years (range: 37 to 80) with 48% &ge; 65 years and 8% &ge; 75 years; 50% Female; 82% White, 15% Asian, 2% Black; 70% ECOG PS 1; 96% had stage IV disease; 99% with non‑squamous histology; 81% former smokers, 12% current smokers, 5% never smokers. All patients received at least 1 prior line of systemic therapy for metastatic NSCLC; 43% received only 1 prior line of therapy, 35% received 2 prior lines of therapy, 23% received 3 prior lines of therapy; 91% received prior anti‑PD‑1/PD‑L1 immunotherapy, 90% received prior platinum‑based chemotherapy, 81% received both platinum‑based chemotherapy and anti‑PD‑1/PD‑L1. The sites of known extra‑thoracic metastasis included 48% bone, 21% brain, and 21% liver.</p><p>&nbsp;</p><p>Efficacy results are summarized in Table 5.</p><p>&nbsp;</p><p><strong>Table 5. Efficacy Results for Patients with </strong><strong><em>KRAS G12C</em></strong><strong>‑mutated NSCLC</strong><strong> Who Received LUMAKRAS in CodeBreaK 100</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Efficacy Parameter</p></td><td style="vertical-align:top"><p>LUMAKRAS</p><p>N=124</p></td></tr><tr><td style="vertical-align:top"><p>Objective Response Rate (95% CI)<sup>a</sup></p></td><td style="vertical-align:top"><p>36 (28, 45)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response rate, %</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Partial response rate, %</p></td><td style="vertical-align:top"><p>35</p></td></tr><tr><td style="vertical-align:top"><p>Duration of Response<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median<sup>b</sup>, months (range)</p></td><td style="vertical-align:top"><p>10.0 (1.3+, 11.1)</p></td></tr><tr><td style="vertical-align:top"><p>Patients with duration &ge; 6 months<sup>c</sup>, %</p></td><td style="vertical-align:top"><p>58%</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>CI = confidence interval</p><p><sup>a </sup>Assessed by Blinded Independent Central Review (BICR)</p><p><sup>b </sup>Estimate using Kaplan‑Meier method</p><p><sup>c </sup>Observed proportion of patients with duration of response beyond landmark time</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of sotorasib have been characterized in healthy subjects and in patients with <em>KRAS&nbsp;G12C</em>‑mutated solid tumors, including NSCLC. Sotorasib exhibited non‑linear, time‑dependent, pharmacokinetics over the dose range of 180&nbsp;mg to 960&nbsp;mg (0.19 to 1 time the approved recommended dosage) once daily with similar systemic exposure (i.e., AUC<sub>0‑24h</sub> and C<sub>max</sub>) across doses at steady‑state. Sotorasib systemic exposure was comparable between film‑coated tablets and film‑coated tablets predispersed in water administered under fasted conditions. Sotorasib plasma concentrations reached steady state within 22 days. No accumulation was observed after repeat LUMAKRAS dosages with a mean accumulation ratio of 0.56 (coefficient of variation (CV):&nbsp;59%).</p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>&nbsp;</p><p>The median time to sotorasib peak plasma concentration is 1 hour.</p><p>&nbsp;</p><p><em>Effect of Food</em></p><p><em>&nbsp;</em></p><p>When 960&nbsp;mg LUMAKRAS was administered with a high‑fat, high‑calorie meal (containing approximately 800 to 1000 calories with 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively) in patients, sotorasib AUC<sub>0‑24h</sub> increased by 25% compared to administration under fasted conditions.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>&nbsp;</p><p>The sotorasib mean volume of distribution (V<sub>d</sub>) at steady state is 211&nbsp;L (CV: 135%). <em>In vitro</em>, sotorasib plasma protein binding is 89%.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>&nbsp;</p><p>The sotorasib mean terminal elimination half‑life is 5 hours (standard deviation (SD): 2). At 960&nbsp;mg LUMAKRAS once daily, the sotorasib steady state apparent clearance is 26.2&nbsp;L/hr (CV: 76%).</p><p><em>&nbsp;</em></p><p><em>Metabolism</em></p><p>The main metabolic pathways of sotorasib are non‑enzymatic conjugation and oxidative metabolism with CYP3As.</p><p><em>&nbsp;</em></p><p><em>Excretion</em></p><p>After a single dose of radiolabeled sotorasib, 74% of the dose was recovered in feces (53% unchanged) and 6% (1%&nbsp;unchanged) in urine.</p><p><strong>&nbsp;</strong></p><p><u>Specific Populations</u></p><p><em>&nbsp;</em></p><p>No clinically meaningful differences in the pharmacokinetics of sotorasib were observed based on age (28 to 86&nbsp;years), sex, race (White, Black and Asian), body weight (36.8 to 157.9&nbsp;kg), line of therapy, ECOG PS (0, 1), mild and moderate renal impairment (eGFR: &ge;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>), or mild hepatic impairment (AST or ALT&nbsp;&lt;&nbsp;2.5&nbsp;&times;&nbsp;ULN or total bilirubin &lt; 1.5 &times; ULN). The effect of severe renal impairment or moderate to severe hepatic impairment on sotorasib pharmacokinetics has not been studied.</p><p>&nbsp;</p><p><strong>Drug Interaction Studies</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Clinical Studies</em></strong></p><p><u>&nbsp;</u></p><p><em>Acid‑Reducing Agents</em>: Coadministration of repeat doses of omeprazole (PPI) with a single dose of LUMAKRAS decreased sotorasib C<sub>max</sub> by 65% and AUC by 57% under fed conditions, and decreased sotorasib C<sub>max</sub> by 57% and AUC by 42% under fasted conditions. Coadministration of a single dose of famotidine (H<sub>2</sub> receptor antagonist) given 10 hours prior to and 2 hours after a single dose of LUMAKRAS under fed conditions decreased sotorasib C<sub>max</sub> by 35% and AUC by 38%<em> .</em></p><p>&nbsp;</p><p><em>Strong CYP3A4 Inducers</em>: Coadministration of repeat doses of rifampin (a strong CYP3A4 inducer) with a single dose of LUMAKRAS decreased sotorasib C<sub>max </sub>by 35% and AUC by 51%.</p><p>&nbsp;</p><p><em>Other Drugs</em>: No clinically meaningful effect on the exposure of sotorasib was observed following coadministration of LUMAKRAS with itraconazole (a combined strong CYP3A4 and P‑gp inhibitor) and a single dose of rifampin (an OATP1B1/1B3 inhibitor), or metformin (a MATE1/MATE2‑K substrate).</p><p><u>&nbsp;</u></p><p><em>CYP3A4 substrates</em>:<em> </em>Coadministration of LUMAKRAS with midazolam (a sensitive CYP3A4 substrate) decreased midazolam C<sub>max</sub> by 48% and AUC by 53%.</p><p><em>&nbsp;</em></p><p><em>P‑gp substrates</em>: Coadministration of LUMAKRAS with digoxin (a P‑gp substrate) increased digoxin C<sub>max</sub> by 91% and AUC by 21%.</p><p><em>&nbsp;</em></p><p><em>MATE1/MATE2‑K substrates</em>: No clinically meaningful effect on the exposure of metformin (a MATE1/MATE2‑K substrate) was observed following coadministration of LUMAKRAS.</p><p>&nbsp;</p><p><strong><em>In Vitro Studies </em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>Cytochrome P450 (CYP) Enzymes</em>:<em> </em>Sotorasib may induce CYP2C8, CYP2C9 and CYP2B6. Sotorasib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6.</p><p><em>&nbsp;</em></p><p><em>Transporter Systems</em>: Sotorasib may inhibit BCRP.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>NONCLINICAL TOXICOLOGY</em></p><p>&nbsp;</p><p><em><u>Carcinogenesis, Mutagenesis, Impairment of Fertility</u></em></p><p>&nbsp;</p><p>Carcinogenicity studies have not been performed with sotorasib.</p><p>&nbsp;</p><p>Sotorasib was not mutagenic in an <em>in vitro</em> bacterial reverse mutation (Ames) assay and was not genotoxic in the <em>in&nbsp;vivo </em>rat micronucleus and comet assays.</p><p>&nbsp;</p><p>Fertility/early embryonic development studies were not conducted with sotorasib. There were no adverse effects on female or male reproductive organs in general toxicology studies conducted in dogs and rats.</p><p>&nbsp;</p><p><em><u>Animal Toxicology and/or Pharmacology</u></em></p><p>&nbsp;</p><p>In rats, renal toxicity including minimal to marked histologic tubular degeneration/necrosis and increased kidney weight, urea nitrogen, creatinine, and urinary biomarkers of renal tubular injury were present at doses resulting in exposures approximately &ge;&nbsp;0.5 times the human AUC at the clinical dose of 960&nbsp;mg. Increases in cysteine S‑conjugate &beta;‑lyase pathway metabolism in the rat kidney compared to human may make rats more susceptible to renal toxicity due to local formation of a putative sulfur‑containing metabolite than humans.</p><p>&nbsp;</p><p>In the 3‑month toxicology study in dogs, sotorasib induced findings in the liver (centrilobular hepatocellular hypertrophy), pituitary gland (hypertrophy of basophils), and thyroid gland (marked follicular cell atrophy, moderate to marked colloid depletion, and follicular cell hypertrophy) at exposures approximately 0.4 times the human exposure based on AUC at the clinical dose of 960&nbsp;mg. These findings may be due to an adaptive response to hepatocellular enzyme induction and subsequent reduced thyroid hormone levels (i.e. secondary hypothyroidism). Although thyroid levels were not measured in dogs, induction of uridine diphosphate glucuronosyltransferase known to be involved in thyroid hormone metabolism was confirmed in the <em>in vitro</em> dog hepatocyte</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Active Ingredient:</strong> sotorasib</p><p><strong>Inactive Ingredients: </strong>microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. Tablet film coating material contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be dispersed with other liquids than that mentioned in section&nbsp;4.2. Acidic beverages (e.g. fruit juices) should also be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at 20&deg;C to 25&deg;C. Excursions permitted from 15&deg;C to 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LUMAKRAS (sotorasib) 120&nbsp;mg tablets are yellow, oblong‑shaped, film‑coated, debossed with &ldquo;AMG&rdquo; on one side and &ldquo;120&rdquo; on the opposite side are supplied as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Carton containing two bottles of 120 tablets with child‑resistant closure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Carton containing one bottle of 240 tablets with child‑resistant closure</p><p>&nbsp;</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product may pose a risk to the environment (see section&nbsp;5.3). Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 USA


MARKETING AUTHORISATION NUMBER(S) 

NDC 55513 488 02
NDC 55513 488 24

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2021


            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>